• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Systematic Review Finds Donations from Hemochromatosis Patients are Safe for Transfusion

September 7, 2012

Hemochromatosis, primarily an inherited blood disorder characterized by iron overload, is treated with routine therapeutic phlebotomy. Although this therapy provides an additional source of blood for transfusion, many blood centers in Europe discard these donations because of concern over bacterial or viral contamination and the non-voluntary nature of this type of donation. Researchers from the Belgian Red Cross recently published a systematic review of six observational studies on the safety and efficacy of donation from hemochromatosis patients, and found that donations from patients without complications are acceptable for transfusion. Two of the studies reviewed found that the blood from hemochromatosis patients was more vulnerable to bacterial growth, but the authors suggest that donations from patients with normalized iron levels would not have this susceptibility. While individuals in the United States with hereditary hemochromatosis have been permitted to donate blood since 2001, many European countries do not have the same policy. The authors call for a coordination of policies between countries to permit hemochromatosis patients to donate blood.

References:

  1. De Buck E, et al. Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion? A systematic review. J Hepatol. 2012 May 30. [Epub ahead of print] 
  2. Guidance for Industry: Variances for Blood Collection from Individuals with Hereditary Hemochromatosis. In: Vaccines, Blood & Biologics. Edited by U.S. Food and Drug Administration. August 2001: Center for Biologics Evaluation and Research (CBER); http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm076719.htm.  Accessed September 7, 2012.

Filed Under

  • Blood Donation
  • News

Recommended

  • Risk of Graft-Versus-Host Disease Dependent on Apheresis Device Used to Collect Allogeneic Stem Cells

  • Combinations of Monoclonal Antibodies Efficiently Suppress Red Blood Cell Alloimmunization in Mice

  • Prothrombin Complex Concentrate for Complex Cardiac Surgery Patients

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley